Search Results - "Knudsen, Anja"

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial by Mirza, Mansoor Raza, MD, Åvall Lundqvist, Elisabeth, PhD, Birrer, Michael J, Prof, dePont Christensen, Rene, PhD, Nyvang, Gitte-Bettina, MD, Malander, Susanne, PhD, Anttila, Maarit, PhD, Werner, Theresa L, MD, Lund, Bente, MD, Lindahl, Gabriel, MD, Hietanen, Sakari, PhD, Peen, Ulla, MD, Dimoula, Maria, MD, Roed, Henrik, DMSci, Ør Knudsen, Anja, MD, Staff, Synnöve, PhD, Krog Vistisen, Anders, MD, Bjørge, Line, Prof, Mäenpää, Johanna U, Prof

“…SummaryBackgroundPlatinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity…”
Get full text

Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer by Meteran, Hanieh, Knudsen, Anja Ør, Jørgensen, Trine Lembrecht, Nielsen, Dorte, Herrstedt, Jørn

“…This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and…”
Get full text

Trends in gynecologic cancer among elderly women in Denmark, 1980-2012 by Ør Knudsen, Anja, Schledermann, Doris, Nyvang, Gitte-Bettina, Mogensen, Ole, Herrstedt, Jørn

“…The aim of this analysis was to describe trends in incidence, mortality, prevalence, and survival in Danish women with gynecologic cancer from 1980-2012…”
Get more information

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial by Valabrega, Giorgio, Pothuri, Bhavana, Oaknin, Ana, Graybill, Whitney S., Sánchez, Ana Beatriz, McCormick, Colleen, Baurain, Jean-François, Tinker, Anna V., Denys, Hannelore, O’Cearbhaill, Roisin E., Hietanen, Sakari, Moore, Richard G., Knudsen, Anja Ør, de La Motte Rouge, Thibault, Heitz, Florian, Levy, Tally, York, Whitney, Gupta, Divya, Monk, Bradley J., González-Martín, Antonio

“…To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer…”
Get full text

Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer by Monk, Bradley J., Romero, Ignacio, Graybill, Whitney, Churruca, Cristina, O'Malley, David M., Knudsen, Anja Ør, Yap, Oi Wah Stephanie, Baurain, Jean-François, Rose, Peter G., Denys, Hannelore, Ghamande, Sharad, Pisano, Carmela, Fabbro, Michel, Braicu, Elena Ioana, Calvert, Paula M., Amit, Amnon, Prendergast, Emily, Taylor, Adekemi, Kheibarshekan, Leila, Zhang, Zhi-Yi, Zajic, Stefan, Jewell, Roxanne C., Gupta, Divya, González-Martín, Antonio

“…•A niraparib population PK model was developed using pooled data from clinical trials.•PopPK/exposure-response analyses support niraparib individualized…”
Get full text

The impact of comprehensive geriatric assessment for optimal treatment of older patients with cancer: A randomized parallel-group clinical trial by Nadaraja, Sambavy, Matzen, Lars-Erik, Jørgensen, Trine Lembrecht, Dysager, Lars, Knudsen, Anja Ør, Jeppesen, Stefan Starup, Möller, Sören, Herrstedt, Jørn

“…The aim was to investigate if oncologic treatment decision based on G8 screening followed by comprehensive geriatric assessment (CGA) and a multidisciplinary…”
Get full text

Outcome of patients with peritoneal metastasis from ovarian cancer treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) by Foslund, Ingrid Terese, von Magius, Sahra Aisha Vinholt, Ainsworth, Alan Patrick, Detlefsen, Sönke, Fristrup, Claus Wilki, Knudsen, Anja Oer, Mortensen, Michael Bau, Tarpgaard, Line Schmidt, Jochumsen, Kirsten Marie, Graversen, Martin

“…There are few data on Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in women with primary unresectable or…”
Get full text

Development, implementation and evaluation of patient decision aids supporting shared decision making in women with recurrent ovarian cancer by Hæe, Mette, Wulff, Christian Nielsen, Fokdal, Lars, Olling, Karina, Jensen, Karina Mølgaard, Hansen, Dorte Gilså, Knudsen, Anja Ør, Lemley, Birthe, Blou, Dorte, Büchmann, Hanne, Steffensen, Karina Dahl

“…Shared decision making (SDM) and use of patient decision aids (PtDAs) are key components in patient-centered care in relapsed ovarian cancer. This paper…”
Get full text

Shared decision making in recurrent ovarian cancer: Implementation of patient decision aids across three departments of oncology in Denmark by Wulff, Christian Nielsen, Hæe, Mette, Hansen, Dorte Gilså, Olling, Karina, Jensen, Karina Mølgaard, Knudsen, Anja Ør, Fokdal, Lars, Steffensen, Karina Dahl

“…Patients with relapsed ovarian cancer are offered multiple treatment options. To match treatment with the individual patient's life situation and preferences,…”
Get full text

1446: MARGARITA: MRLinac Boost for Gynecological Cancers if brachytherapy is not feasible. Initial results by van Lier, Astrid, Bernchou, Uffe, van der Leij, Femke, Knudsen, Anja Ør, Hes, Jochem, Nyvang, Gitte-Bettina, Zweemer, Ronald, van Breugel, Eline Groot, Hazell, Irene, Schytte, Tine, Bertelsen, Anders Smedegaar, Jürgenliemk-Schulz, Ina

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Graybill, Whitney, Vergote, Ignace, Pothuri, Bhavana, Anttila, Maarit, O'Malley, David, Lorusso, Domenica, Haggerty, Ashley, Fabbro, Michel, Chan, John, Heitz, Florian, Willmott, Lyndsay, Bruchim, Ilan, Zhuo, Ying, Estévez-García, Purificación, Monk, Bradley, Denys, Hannelore, Knudsen, Anja, Tinker, Anna, Sánchez, Luis Manso, Provencher, Diane, Barretina-Ginesta, M. Pilar, Hartman, John, Booth, Donna, González-Martín, Antonio

Get full text

Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial by Pothuri, Bhavana, Valabrega, Giorgio, Oaknin, Ana, Graybill, Whitney, Sánchez, Ana Beatriz, McCormick, Colleen, Baurain, Jean-François, Tinker, Anna, Denys, Hannelore, O'Cearbhaill, Roisin, Hietanen, Sakari, Moore, Richard, Knudsen, Anja, de La Motte Rouge, Thibault, Heitz, Florian, Levy, Tally, York, Whitney, Malinowska, Izabela, Monk, Bradley, González-Martín, Antonio

Get full text

OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts by Selle, Frederic, Asselain, Bernard, Montestruc, François, Bazan, Fernando, Pardo, Beatriz, Salutari, Vanda, Marmé, Frederik, Ør Knudsen, Anja, Bologna, Alessandra, Madry, Radoslaw, Glasspool, Rosalind, Henry, Stéphanie, Korach, Jacob, Lheureux, Stephanie, Shaw, Bob, Santaballa, Ana, Cioffi, Raffaella, Canzler, Ulrich, Lortholary, Alain, Pujade-Lauraine, Eric

“…5558 Background: In the Phase IIIb OReO/ENGOT Ov-38 trial (NCT03106987), maintenance olaparib (O) rechallenge significantly improved progression-free survival…”
Get full text

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24 by Mirza, Mansoor Raza, Avall-Lundqvist, Elisabeth, Birrer, Michael J., Christensen, Rene dePont, Nyvang, Gitte-Bettina, Malander, Susanne, Anttila, Maarit, Werner, Theresa Louise, Lund, Bente, Lindahl, Gabriel, Hietanen, Sakari, Peen, Ulla, Dimoula, Maria, Roed, Henrik, Knudsen, Anja Ør, Boufercha, Louisa, Staff, Synnove, Krog Vistisen, Anders, Bjørge, Line, Maenpaa, Johanna Unelma

“…Abstract only 5505 Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum based combination chemotherapy ±…”
Get full text

Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study by Mirza, Mansoor Raza, Nyvang, Gitte-Betina, Lund, Bente, Christensen, Rene dePont, Werner, Theresa Louise, Malander, Susanne, Bjørge, Line, Birrer, Michael J., Anttila, Maarit, Lindahl, Gabriel, Hietanen, Sakari, Dimoula, Maria, Peen, Ulla, Madsen, Kristine, Knudsen, Anja, Staff, Synnove, Buchner Vinum, Nicole, Kjeldsen, Maj Kamille, Avall-Lundqvist, Elisabeth, Maenpaa, Johanna Unelma

“…Abstract only 6012 Background: We previously reported significantly improved progression-free survival (PFS) with the chemotherapy-free regimen of niraparib…”
Get full text

Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of peritoneal metastases by Graversen, Martin, Detlefsen, Sönke, Knudsen, Anja Ør, Pfeiffer, Per, Mortensen, Michael Bau

“…Pressurised intraperitoneal aerosol chemotherapy (PIPAC) was introduced in Denmark in 2015. More than 100 Danish patients with peritoneal metastases (PM) have…”
Get more information

Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial by Mirza, Mansoor Raza, Maenpaa, Johanna Unelma, Braicu, Elena Ioana, Vergote, Ignace, Berton-Rigaud, Dominique, Rosenberg, Per, Huober, Jens Bodo, Denys, Hannelore, Joly Lobbedez, Florence, Kristensen, Gunnar, Reimer, Toralf, Kridelka, Frederic, Floquet, Anne, Knudsen, Anja, Aktas, Bahriye, Baurain, Jean-Francois, Follana, Philippe, Juhler-Nøttrup, Trine, Jederud, Christina, Sehouli, Jalid

“…Abstract only TPS5611 Background: Endometrial cancer (EC) patients with advanced and recurrent disease relapse despite treatment with combination chemotherapy…”
Get full text